IL240196B - Amide compounds, preparations containing them and their uses - Google Patents
Amide compounds, preparations containing them and their usesInfo
- Publication number
- IL240196B IL240196B IL240196A IL24019615A IL240196B IL 240196 B IL240196 B IL 240196B IL 240196 A IL240196 A IL 240196A IL 24019615 A IL24019615 A IL 24019615A IL 240196 B IL240196 B IL 240196B
- Authority
- IL
- Israel
- Prior art keywords
- compositions
- same
- amide compounds
- amide
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361759062P | 2013-01-31 | 2013-01-31 | |
| PCT/US2014/013667 WO2014120820A1 (en) | 2013-01-31 | 2014-01-29 | Amides as modulators of sodium channels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL240196A0 IL240196A0 (en) | 2015-09-24 |
| IL240196B true IL240196B (en) | 2019-08-29 |
Family
ID=50114569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL240196A IL240196B (en) | 2013-01-31 | 2015-07-28 | Amide compounds, preparations containing them and their uses |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9108903B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2951155B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6346622B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102226588B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN104968647B (cg-RX-API-DMAC7.html) |
| AR (1) | AR094668A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014212431B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015018284B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2898653C (cg-RX-API-DMAC7.html) |
| IL (1) | IL240196B (cg-RX-API-DMAC7.html) |
| MX (1) | MX359882B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2658920C2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201505954RA (cg-RX-API-DMAC7.html) |
| TW (1) | TWI659945B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014120820A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014212426B8 (en) | 2013-01-31 | 2018-05-10 | Vertex Pharmaceuticals Incorporated | Quinoline and Quinoxaline Amides as Modulators of Sodium Channels |
| CN108164457B (zh) | 2013-01-31 | 2021-07-09 | 沃泰克斯药物股份有限公司 | 作为钠通道调节剂的吡啶酮酰胺 |
| CA2918365C (en) | 2013-07-19 | 2021-09-07 | Vertex Pharmaceuticals Incorporated | Sulfonamides as modulators of sodium channels |
| ES2986650T3 (es) | 2013-12-13 | 2024-11-12 | Vertex Pharma | Proceso y productos intermedios para preparar profármacos de amidas de piridona útiles como moduladores de los canales de sodio |
| ES2927712T3 (es) | 2017-05-16 | 2022-11-10 | Vertex Pharma | Amidas deuteradas de piridona y profármacos de las mismas como moduladores de canales de sodio |
| ES3008911T3 (en) | 2017-07-11 | 2025-03-25 | Vertex Pharma | Carboxamides as modulators of sodium channels |
| TW202002971A (zh) | 2018-02-12 | 2020-01-16 | 美商維泰克斯製藥公司 | 治療疼痛的方法 |
| CA3117927A1 (en) * | 2018-11-02 | 2020-05-07 | Merck Sharp & Dohme Corp. | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors |
| EP3873468A4 (en) | 2018-11-02 | 2022-10-26 | Merck Sharp & Dohme LLC | 2-AMINO-N-PHENYL-NICOTINAMIDES AS NAV1.8 INHIBITORS |
| BR112021012909A2 (pt) * | 2019-01-04 | 2021-09-14 | Jiangsu Hengrui Medicine Co., Ltd. | Derivado de 6-oxo-1,6-di-hidropiridazina, método de preparação do mesmo e uso médico do mesmo |
| US12441703B2 (en) | 2019-01-10 | 2025-10-14 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| WO2020146612A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
| WO2020169042A1 (zh) * | 2019-02-20 | 2020-08-27 | 江苏恒瑞医药股份有限公司 | 6-氧代-1,6-二氢哒嗪类前药衍生物、其制备方法及其在医药上的应用 |
| WO2020176763A1 (en) | 2019-02-27 | 2020-09-03 | Vertex Pharmaceuticals Incorporated | Dosage form comprising prodrug of na 1.8 sodium channel inhibitor |
| WO2020219867A1 (en) | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Pyridone amide co-crystal compositions for the treatment of pain |
| US20230303495A9 (en) * | 2019-09-12 | 2023-09-28 | Orion Corporation | Pyridine oxynitride, preparation method therefor and use thereof |
| PT4069691T (pt) | 2019-12-06 | 2024-12-18 | Vertex Pharma | Tetrahidrofuranos substituídos como moduladores dos canais de sódio |
| CN114437062B (zh) * | 2020-04-30 | 2024-05-17 | 成都海博为药业有限公司 | 一种可作为钠通道调节剂的化合物及其用途 |
| TWI806073B (zh) | 2020-06-17 | 2023-06-21 | 美商默沙東有限責任公司 | 作為nav1.8抑制劑之2-氧基咪唑啶-4-甲醯胺 |
| CN113880771B (zh) * | 2020-07-03 | 2023-09-19 | 福建盛迪医药有限公司 | 一种选择性Nav抑制剂的结晶形式及其制备方法 |
| CN114031518B (zh) * | 2020-12-08 | 2023-08-18 | 成都海博为药业有限公司 | 一种苄胺或苄醇衍生物及其用途 |
| CN112225695B (zh) * | 2020-12-15 | 2021-03-02 | 上海济煜医药科技有限公司 | 一种氮氧化合物及其制备方法和用途 |
| KR20240019064A (ko) * | 2021-03-11 | 2024-02-14 | 상하이 제민케어 파마슈티칼 컴퍼니 리미티드 | 피리딘 질소 산화물 화합물의 결정 형태 및 이의 용도 |
| US20220380338A1 (en) | 2021-05-07 | 2022-12-01 | Merck Sharp & Dohme Llc | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors |
| AU2022286438A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
| EP4346818B1 (en) | 2021-06-04 | 2025-12-03 | Vertex Pharmaceuticals Incorporated | Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide |
| CN117858875A (zh) | 2021-06-04 | 2024-04-09 | 沃泰克斯药物股份有限公司 | 羟基和(卤代)烷氧基取代的四氢呋喃作为钠通道调节剂 |
| CA3221938A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
| WO2022256702A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| GEAP202416430A (en) | 2021-06-04 | 2024-03-25 | Vertex Pharma | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
| JP2025513454A (ja) | 2022-04-22 | 2025-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の治療のためのヘテロアリール化合物 |
| WO2023205778A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| CN119677737A (zh) | 2022-04-22 | 2025-03-21 | 沃泰克斯药物股份有限公司 | 用于治疗疼痛的杂芳基化合物 |
| CA3257285A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | HETEROARYL COMPOUNDS FOR PAIN RELIEF |
| JP2025516005A (ja) | 2022-04-25 | 2025-05-23 | サイトワン セラピューティクス インコーポレイテッド | 疼痛の処置のためのｎａｖ１．８の二環式複素環アミド阻害剤 |
| IL321269A (en) | 2022-12-06 | 2025-08-01 | Vertex Pharma | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
| TW202434235A (zh) * | 2023-01-18 | 2024-09-01 | 芬蘭商奧利安公司 | ３－（４，５－二氯－２－（４－（三氟甲氧基）苯氧基）苯甲醯胺基）吡啶１－氧化物的製備方法 |
| WO2025090511A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing modulators of sodium channels and solid forms of the same for treating pain |
| TW202523313A (zh) | 2023-10-23 | 2025-06-16 | 美商維泰克斯製藥公司 | 用於治療疼痛之雜芳基化合物 |
| WO2025090480A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2025090516A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing compounds for treating pain and solid forms thereof |
| US20250186419A1 (en) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Dosing regimens for treating pain |
| WO2025160286A1 (en) | 2024-01-24 | 2025-07-31 | Siteone Therapeutics, Inc. | 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2511231A (en) * | 1949-03-26 | 1950-06-13 | Eastman Kodak Co | 1-cyanophenyl-3-acylamino-5-pyrazolone couplers for color photography |
| MX2008013194A (es) | 2006-04-11 | 2008-12-01 | Vertex Pharma | Composiciones utiles como inhibidores de canales de sodio regulados por voltaje. |
| KR20100075631A (ko) | 2007-10-11 | 2010-07-02 | 버텍스 파마슈티칼스 인코포레이티드 | 전압개폐 나트륨 채널의 억제제로서 유용한 아릴 아미드 |
| CN101855210A (zh) * | 2007-10-11 | 2010-10-06 | 沃泰克斯药物股份有限公司 | 用作电压-门控钠通道抑制剂的酰胺类 |
| EP2227453B1 (en) | 2007-10-11 | 2016-03-09 | Vertex Pharmaceuticals Incorporated | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels |
| CN102448937A (zh) * | 2009-05-29 | 2012-05-09 | 拉夸里亚创药株式会社 | 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物 |
-
2014
- 2014-01-29 EP EP14704981.1A patent/EP2951155B1/en active Active
- 2014-01-29 BR BR112015018284-4A patent/BR112015018284B1/pt not_active IP Right Cessation
- 2014-01-29 CN CN201480006878.4A patent/CN104968647B/zh active Active
- 2014-01-29 AR ARP140100282A patent/AR094668A1/es unknown
- 2014-01-29 RU RU2015136779A patent/RU2658920C2/ru active
- 2014-01-29 SG SG11201505954RA patent/SG11201505954RA/en unknown
- 2014-01-29 AU AU2014212431A patent/AU2014212431B2/en active Active
- 2014-01-29 WO PCT/US2014/013667 patent/WO2014120820A1/en not_active Ceased
- 2014-01-29 US US14/167,741 patent/US9108903B2/en active Active
- 2014-01-29 KR KR1020157023600A patent/KR102226588B1/ko not_active Expired - Fee Related
- 2014-01-29 JP JP2015556113A patent/JP6346622B2/ja active Active
- 2014-01-29 TW TW103103690A patent/TWI659945B/zh active
- 2014-01-29 CA CA2898653A patent/CA2898653C/en active Active
- 2014-01-29 MX MX2015009591A patent/MX359882B/es active IP Right Grant
-
2015
- 2015-07-27 US US14/809,841 patent/US9421196B2/en active Active
- 2015-07-28 IL IL240196A patent/IL240196B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP2951155A1 (en) | 2015-12-09 |
| MX359882B (es) | 2018-10-15 |
| BR112015018284B1 (pt) | 2023-03-07 |
| AR094668A1 (es) | 2015-08-19 |
| IL240196A0 (en) | 2015-09-24 |
| NZ710293A (en) | 2020-09-25 |
| US9108903B2 (en) | 2015-08-18 |
| US9421196B2 (en) | 2016-08-23 |
| TW201443005A (zh) | 2014-11-16 |
| EP2951155B1 (en) | 2019-06-19 |
| WO2014120820A9 (en) | 2015-07-02 |
| RU2015136779A (ru) | 2017-03-07 |
| US20150328196A1 (en) | 2015-11-19 |
| MX2015009591A (es) | 2016-04-15 |
| WO2014120820A1 (en) | 2014-08-07 |
| CA2898653A1 (en) | 2014-08-07 |
| CN104968647B (zh) | 2018-01-26 |
| CN104968647A (zh) | 2015-10-07 |
| BR112015018284A2 (pt) | 2017-07-18 |
| JP6346622B2 (ja) | 2018-06-20 |
| JP2016508500A (ja) | 2016-03-22 |
| AU2014212431A1 (en) | 2015-08-06 |
| CA2898653C (en) | 2021-09-28 |
| KR20150118964A (ko) | 2015-10-23 |
| TWI659945B (zh) | 2019-05-21 |
| KR102226588B1 (ko) | 2021-03-11 |
| RU2658920C2 (ru) | 2018-06-26 |
| AU2014212431B2 (en) | 2018-04-05 |
| SG11201505954RA (en) | 2015-08-28 |
| HK1217692A1 (en) | 2017-01-20 |
| US20140221435A1 (en) | 2014-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL240196B (en) | Amide compounds, preparations containing them and their uses | |
| IL274355B (en) | Aza-pyridone compounds and their uses | |
| IL269964A (en) | Pyridone amide compounds, compositions containing them and uses thereof | |
| IL246061A0 (en) | Prodrugs of pyridone amide, preparations containing them and their uses | |
| IL240091B (en) | Quinoline and quinoxaline amides, preparations containing them and their uses | |
| IL244850A0 (en) | Stabilized epinaconazole preparations, and their uses | |
| IL243752A0 (en) | Multispecific antibodies, preparations containing them and their uses | |
| IL241330A0 (en) | pk - dna suppressor compounds, preparations containing them and their uses | |
| IL241355B (en) | Pyrazole-amide compounds, preparations containing them and their uses | |
| IL241352A0 (en) | Compounds of pyruvate kinase plants, preparations containing them and their uses | |
| IL241225A0 (en) | Plant-based compositions and their uses | |
| IL238958A0 (en) | Glutamase inhibitors, preparations containing them and their uses | |
| IL234014A0 (en) | Cycloalkane derivatives, preparations containing them and their uses | |
| IL238959A0 (en) | Glutamase inhibitors, preparations containing them and their uses | |
| IL243495A0 (en) | Compressed piperidine amides, preparations containing them and their uses | |
| GB201323008D0 (en) | Compounds and uses thereof | |
| GB201321693D0 (en) | Composition and uses thereof | |
| IL233824A (en) | Compounds 1h - Indazole - 3 - Carboxamide, preparations containing them and their use | |
| IL276126B (en) | Preparations containing l-4-chloroquinonerine and their uses | |
| IL241358A0 (en) | Compounds derived from mannose, preparations containing them and their uses | |
| IL241359A0 (en) | Converted indole-5-ol derivatives, preparations containing them and their uses | |
| EP2964610A4 (en) | VINYL SULFON-BASED 18F LABELING COMPOSITIONS AND METHOD AND USES THEREOF | |
| GB201307233D0 (en) | Compounds and uses thereof | |
| IL233682A0 (en) | Modified phenylazole derivatives, preparations containing them and their uses | |
| SG11201600266VA (en) | Uv absorbing compounds, compositions comprising same and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |